Marker X CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Marker X provides advanced AI proteomics services that combine artificial intelligence with cutting-edge protein analysis technology to promote early disease detection and biomedical innovation. Their core offerings include AI Proteomics Early Cancer Scre
The content above was translated by Ai
Founded Year
2020
Unified Business No.
82941917
Status
Active
Number of Employees
0
Total Paid-in
Capital
110,823,864 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
At Marker X, we are dedicated to providing the most accurate and effective multi-cancer early detection (MCED) method. Through the use of cutting-edge proteomic analysis, and artificial intelligence, we are able to detect cancer at its earliest stages, giving patients the best chance for pursuing their lives and creating value to the world.
The content above was translated by Ai
